Jasmin Tiro to Uterine Cervical Neoplasms
This is a "connection" page, showing publications Jasmin Tiro has written about Uterine Cervical Neoplasms.
Connection Strength
7.826
-
The impact of intimate partner violence on breast and cervical cancer survivors in an integrated, safety-net setting. J Cancer Surviv. 2020 12; 14(6):906-914.
Score: 0.607
-
Evaluating Screening Participation, Follow-up, and Outcomes for Breast, Cervical, and Colorectal Cancer in the PROSPR Consortium. J Natl Cancer Inst. 2020 03 01; 112(3):238-246.
Score: 0.591
-
Understanding Patients' Perspectives and Information Needs Following a Positive Home Human Papillomavirus Self-Sampling Kit Result. J Womens Health (Larchmt). 2019 03; 28(3):384-392.
Score: 0.542
-
Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1398-1406.
Score: 0.533
-
Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS. 2018 08 24; 32(13):1861-1870.
Score: 0.532
-
Characterizing safety-net providers' HPV vaccine recommendations to undecided parents: A pilot study. Patient Educ Couns. 2016 09; 99(9):1452-60.
Score: 0.458
-
Knowledge and intention to participate in cervical cancer screening after the human papillomavirus vaccine. Vaccine. 2011 Jun 06; 29(25):4238-43.
Score: 0.319
-
Human papillomavirus and cervical cancer behavioral surveillance in the US. Cancer. 2008 Nov 15; 113(10 Suppl):3013-30.
Score: 0.270
-
What do women in the U.S. know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):288-94.
Score: 0.239
-
Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial. JAMA. 2023 11 28; 330(20):1971-1981.
Score: 0.192
-
Disparities in Gynecologic Cancers. Cancer J. 2023 Nov-Dec 01; 29(6):343-353.
Score: 0.191
-
Timing of Colposcopy and Risk of Cervical Cancer. Obstet Gynecol. 2023 11 01; 142(5):1125-1134.
Score: 0.188
-
Racial and Ethnic Disparities in Cervical Cancer Screening From Three U.S. Healthcare Settings. Am J Prev Med. 2023 10; 65(4):667-677.
Score: 0.184
-
Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening. JAMA Netw Open. 2023 03 01; 6(3):e234052.
Score: 0.182
-
Provider beliefs in effectiveness and recommendations for primary HPV testing in 3 health-care systems. JNCI Cancer Spectr. 2023 01 03; 7(1).
Score: 0.180
-
Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2022 Nov 01; 5(11):e2244343.
Score: 0.178
-
Factors associated with timely colposcopy following an abnormal cervical cancer test result. Prev Med. 2022 11; 164:107307.
Score: 0.177
-
Design of a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake in a U.S. healthcare system: The STEP trial. Contemp Clin Trials. 2022 11; 122:106960.
Score: 0.177
-
Gaps in the screening process for women diagnosed with cervical cancer in four diverse US health care settings. Cancer Med. 2023 02; 12(3):3705-3717.
Score: 0.176
-
Variation in the receipt of human papilloma virus co-testing for cervical screening: Individual, provider, facility and healthcare system characteristics. Prev Med. 2022 01; 154:106871.
Score: 0.166
-
De-implementation of cervical cancer screening before age 21. Prev Med. 2021 12; 153:106815.
Score: 0.165
-
T Cell Receptor Repertoires Acquired via Routine Pap Testing May Help Refine Cervical Cancer and Precancer Risk Estimates. Front Immunol. 2021; 12:624230.
Score: 0.159
-
Out of reach? Correlates of cervical cancer underscreening in women with varying levels of healthcare interactions in a United States integrated delivery system. Prev Med. 2021 04; 145:106410.
Score: 0.157
-
Authors' response: Cost-effectiveness evidence for HPV self-sampling could be improved by giving greater attention to vulnerable populations. Prev Med. 2020 10; 139:106081.
Score: 0.149
-
Reactions of women underscreened for cervical cancer who received unsolicited human papillomavirus self-sampling kits. J Med Screen. 2020 09; 27(3):146-156.
Score: 0.145
-
Effect of Mailed Human Papillomavirus Test Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection, and Treatment: A Randomized Clinical Trial. JAMA Netw Open. 2019 11 01; 2(11):e1914729.
Score: 0.144
-
Cervical cancer screening research in the PROSPR I consortium: Rationale, methods and baseline findings from a US cohort. Int J Cancer. 2019 03 15; 144(6):1460-1473.
Score: 0.136
-
Variation in Screening Abnormality Rates and Follow-Up of Breast, Cervical and Colorectal Cancer Screening within the PROSPR Consortium. J Gen Intern Med. 2016 Apr; 31(4):372-9.
Score: 0.113
-
Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015 Jun; 107(6):djv120.
Score: 0.106
-
Effects of socioeconomic status and health care access on low levels of human papillomavirus vaccination among Spanish-speaking Hispanics in California. Am J Public Health. 2013 Feb; 103(2):270-2.
Score: 0.090
-
Evaluating associations between sources of information, knowledge of the human papillomavirus, and human papillomavirus vaccine uptake for adult women in California. Vaccine. 2012 Apr 19; 30(19):3003-8.
Score: 0.085
-
Multilevel correlates for human papillomavirus vaccination of adolescent girls attending safety net clinics. Vaccine. 2012 Mar 16; 30(13):2368-75.
Score: 0.083
-
One in four California adolescent girls have had human papillomavirus vaccination. Policy Brief UCLA Cent Health Policy Res. 2009 Feb; (PB2009-3):1-6.
Score: 0.069
-
Anal Cancer and Anal Cancer Screening Knowledge, Attitudes, and Perceived Risk Among Women Living With HIV. J Low Genit Tract Dis. 2021 Jan 01; 25(1):43-47.
Score: 0.039
-
Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis. Cancer. 2021 03 15; 127(6):850-864.
Score: 0.039
-
Cost-effectiveness studies of HPV self-sampling: A systematic review. Prev Med. 2020 03; 132:105953.
Score: 0.037
-
Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials. 2018 01; 64:77-87.
Score: 0.031